ArticleFrontiers in oncology2026
Association of systemic immune-inflammation index with all-cause mortality in lung cancer patients undergoing radiotherapy: a retrospective cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The systemic immune-inflammation index (SII) has emerged as a widely studied inflammatory biomarker reflecting the balance between host inflammatory and immune status, although evidence in lung cancer patients undergoing radiotherapy remains limited. This study aimed to investigate the association between baseline SII and all-cause mortality in lung cancer patients undergoing radiotherapy. Methods: A retrospective cohort study was conducted including 489 lung cancer patients who received radiotherapy from January 2022 to January 2025. Baseline SII was calculated as platelet count × neutrophil count/lymphocyte count. Patients were categorized into three tertiles based on SII values: T1 (low SII, ≤480.69, n = 159), T2 (moderate SII, 480.69-857.56, n = 171), and T3 (high SII, >857.56, n = 159). The primary endpoint was all-cause mortality, with follow-up until death or September 2025. Cox proportional hazards models, subgroup analyses, Kaplan-Meier survival analysis, receiver operating characteristic (ROC) curve analysis, and restricted cubic spline (RCS) analysis were employed to assess the relationship between SII and mortality risk. Results: During a median follow-up of 19.9 months, 269 patients (55.0%) died from all causes. Kaplan-Meier analysis showed significantly poorer survival in patients with high SII (T3) compared with those in the low SII group (T1, P < 0.001). In multivariable Cox models, SII remained an independent predictor of all-cause mortality. When analyzed as tertiles, the fully adjusted hazard ratios (HRs) were 2.583 (95% confidence interval [CI]: 1.630-4.095) for T2 and 4.475 (95% CI: 2.841-7.047) for T3 compared with T1 (P for trend < 0.001). Standardized SII also consistently predicted higher mortality risk (HR = 1.222, 95% CI: 1.108-1.347, P < 0.001). Subgroup analyses confirmed stronger associations in patients aged ≤ 60 years and in both sexes. ROC curve analysis demonstrated that SII had strong discriminative power for predicting all-cause mortality, with an area under the curve (AUC) of 0.831 (95% CI: 0.794-0.865, P < 0.001). RCS analysis revealed a significant non-linear relationship between SII and all-cause mortality (P-overall < 0.001; P-nonlinear < 0.001). Conclusion: High baseline SII predicts higher all-cause mortality in lung cancer patients receiving radiotherapy, indicating its value as a simple and cost-effective prognostic biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.